Halozyme Therapeutics (HALO) Financials

$54.54 +0.79 (+1.47%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$53.34 -1.20 (-2.19%)

As of 05/23/2025 07:56 PM Eastern

Annual Income Statements for Halozyme Therapeutics

This table shows Halozyme Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Net Income / (Loss) Attributable to Common Shareholders	444	282	202	403	129	-72	-80	63	-103	-32
Consolidated Net Income / (Loss)	444	282	202	403	129	-72	-80	63	-103	-32
Net Income / (Loss) Continuing Operations	444	282	202	403	129	-72	-80	63	-103	-32
Total Pre-Tax Income	557	348	249	249	129	-72	-80	62	-102	-32
Total Operating Income	551	338	268	276	144	-68	-69	81	-83	-27
Total Gross Profit	856	637	521	362	224	150	142	285	113	106
Total Revenue	1,015	829	660	443	268	196	152	317	147	135
Operating Revenue	1,015	829	660	443	268	196	152	317	147	135
Total Cost of Revenue	159	192	139	81	43	46	10	31	33	29
Operating Cost of Revenue	159	192	139	81	43	46	10	31	33	29
Total Operating Expenses	304	299	253	86	80	218	211	204	197	133
Selling, General & Admin Expense	154	149	144	50	46	77	61	54	46	40
Research & Development Expense	79	76	67	36	34	141	150	151	151	93
Amortization Expense	71	74	43	0.00	0.00	-	-	-	-	-
Total Other Income / (Expense), net	5.66	11	-19	-27	-15	-4.64	-10	-19	-19	-4.78
Interest Expense	18	19	20	28	20	12	18	22	20	5.20
Interest & Investment Income	0.00	13	0.00	0.00	-	-	-	-	-	-
Other Income / (Expense), net	24	16	1.05	1.10	5.43	6.99	7.58	2.59	1.33	0.42
Income Tax Expense	113	67	47	-154	0.22	-0.01	0.54	-1.36	1.16	0.00
Basic Earnings per Share	$3.50	$2.13	$1.48	$2.86	$0.95	($0.50)	($0.56)	$0.46	($0.81)	($0.25)
Weighted Average Basic Shares Outstanding	126.83M	131.93M	136.84M	140.65M	136.21M	144.33M	143.60M	136.42M	127.96M	126.70M
Diluted Earnings per Share	$3.43	$2.10	$1.44	$2.74	$0.91	($0.50)	($0.56)	$0.45	($0.81)	($0.25)
Weighted Average Diluted Shares Outstanding	129.42M	134.20M	140.61M	146.80M	141.46M	144.33M	143.60M	139.07M	127.96M	126.70M
Weighted Average Basic & Diluted Shares Outstanding	123.15M	126.82M	135.37M	137.70M	135.28M	144.33M	143.60M	0.00	127.20M	126.70M

This table shows Halozyme Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	118	137	137	93	77	85	82	75	40	58	62
Consolidated Net Income / (Loss)	118	137	137	93	77	85	82	75	40	58	62
Net Income / (Loss) Continuing Operations	118	137	137	93	77	85	82	75	40	58	62
Total Pre-Tax Income	144	178	165	118	96	101	102	93	52	71	74
Total Operating Income	142	176	163	117	96	101	88	94	54	75	83
Total Gross Profit	216	256	241	192	168	178	161	171	127	139	162
Total Revenue	265	298	290	231	196	230	216	221	162	181	209
Operating Revenue	265	298	290	231	196	230	216	221	162	181	209
Total Cost of Revenue	48	42	49	40	28	52	55	50	35	42	47
Operating Cost of Revenue	48	42	49	40	28	52	55	50	35	42	47
Total Operating Expenses	75	80	77	75	72	77	73	77	73	65	78
Selling, General & Admin Expense	42	42	41	36	35	38	35	39	37	38	34
Research & Development Expense	15	20	18	21	19	21	17	20	18	23	17
Amortization Expense	18	18	18	18	18	18	20	18	18	4.55	27
Total Other Income / (Expense), net	2.29	2.71	1.95	0.51	0.49	0.14	13	-1.30	-1.56	-3.72	-9.59
Interest Expense	4.53	4.54	4.52	4.52	4.51	5.22	4.51	4.49	4.54	4.57	10
Other Income / (Expense), net	6.82	7.25	6.47	5.03	4.99	5.36	4.79	3.19	2.98	0.85	0.64
Income Tax Expense	26	41	28	24	19	16	20	18	13	13	12
Basic Earnings per Share	$0.96	$1.08	$1.08	$0.73	$0.61	$0.65	$0.62	$0.57	$0.29	$0.43	$0.45
Weighted Average Basic Shares Outstanding	123.22M	126.83M	126.85M	127.12M	126.94M	131.93M	131.97M	131.73M	135.03M	136.84M	136.53M
Diluted Earnings per Share	$0.93	$1.06	$1.05	$0.72	$0.60	$0.64	$0.61	$0.56	$0.29	$0.41	$0.44
Weighted Average Diluted Shares Outstanding	126.64M	129.42M	130.13M	129.22M	128.89M	134.20M	134.08M	133.54M	137.90M	140.61M	139.39M
Weighted Average Basic & Diluted Shares Outstanding	123.22M	123.15M	127.23M	126.68M	127.27M	126.82M	132.10M	131.92M	131.68M	135.37M	135.21M

This table details how cash moves in and out of Halozyme Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Net Change in Cash & Equivalents	-2.52	-116	115	-29	28	62	-111	102	23	-18
Net Cash From Operating Activities	479	389	240	299	55	-85	-50	134	-50	-37
Net Cash From Continuing Operating Activities	479	389	240	299	55	-85	-49	134	-50	-37
Net Income / (Loss) Continuing Operations	444	282	202	403	129	-72	-80	63	-103	-32
Consolidated Net Income / (Loss)	444	282	202	403	129	-72	-80	63	-103	-32
Depreciation Expense	10	11	6.49	3.00	3.28	4.07	2.39	2.16	2.41	1.68
Amortization Expense	67	75	52	5.90	15	0.02	-1.55	1.46	16	1.24
Non-Cash Adjustments To Reconcile Net Income	46	25	26	40	12	33	39	31	26	22
Changes in Operating Assets and Liabilities, net	-89	-4.17	-46	-152	-104	-51	-8.71	37	8.38	-30
Net Cash From Investing Activities	-263	-97	-487	-406	78	-5.55	2.49	-164	-77	5.89
Net Cash From Continuing Investing Activities	-263	-97	-487	-406	78	-5.55	2.49	-164	-77	5.89
Purchase of Property, Plant & Equipment	-11	-15	-4.81	-1.46	-2.50	-4.04	-4.66	-1.54	-3.14	-2.36
Acquisitions	0.00	0.00	-999	0.00	0.00	-	-	-	-	-
Purchase of Investments	-648	-293	-255	-653	-226	-390	-311	-398	-155	-71
Sale of Property, Plant & Equipment	0.00	0.00	26	0.00	1.08	0.00	0.00	-	-	-
Sale and/or Maturity of Investments	396	211	746	248	306	388	318	236	82	80
Net Cash From Financing Activities	-219	-408	362	78	-106	153	-64	132	151	13
Net Cash From Continuing Financing Activities	-219	-408	362	78	-106	153	-64	132	151	13
Repayment of Debt	0.00	-13	-455	-369	-20	-108	-78	-16	-54	0.00
Repurchase of Common Equity	-250	-402	-200	-350	-150	-200	0.00	0.00	-	-
Issuance of Debt	0.00	0.00	1,072	785	0.00	447	0.00	0.00	203	0.00
Issuance of Common Equity	31	7.88	14	13	63	14	14	148	1.87	13
Other Financing Activities, net	0.00	0.00	-69	0.00	0.00	-	-	-	-	-
Cash Interest Paid	11	11	6.11	3.30	6.53	9.03	17	20	3.89	3.78
Cash Income Taxes Paid	81	32	16	-0.38	0.18	0.19	0.22	3.02	1.44	0.00

This table details how cash moves in and out of Halozyme Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	60	-38	-34	23	46	-156	53	124	-138	87	56
Net Cash From Operating Activities	154	178	115	56	129	102	132	67	87	82	70
Net Cash From Continuing Operating Activities	154	178	115	56	129	102	132	67	87	82	70
Net Income / (Loss) Continuing Operations	118	137	137	93	77	85	82	75	40	58	62
Consolidated Net Income / (Loss)	118	137	137	93	77	85	82	75	40	58	62
Depreciation Expense	2.69	2.65	2.60	2.57	2.44	2.93	2.74	2.79	2.62	2.56	2.01
Amortization Expense	18	17	16	17	17	17	21	18	19	6.51	31
Non-Cash Adjustments To Reconcile Net Income	11	12	13	11	10	14	-4.63	4.48	12	6.09	8.81
Changes in Operating Assets and Liabilities, net	4.61	10	-54	-68	23	-17	32	-33	14	9.60	-34
Net Cash From Investing Activities	-90	29	-167	-42	-83	-8.29	-83	55	-60	-1.75	-1.01
Net Cash From Continuing Investing Activities	-90	29	-167	-42	-83	-8.29	-83	55	-60	-1.75	-1.01
Purchase of Property, Plant & Equipment	-0.95	-3.05	-1.52	-2.58	-3.55	-2.60	-2.94	1.62	-11	-2.34	-1.01
Purchase of Investments	-140	-51	-304	-93	-199	-21	-162	-	-110	-30	-
Sale and/or Maturity of Investments	50	84	138	54	120	16	81	53	61	20	-
Net Cash From Financing Activities	-3.32	-246	19	9.48	-0.49	-250	4.10	2.45	-165	6.33	-12
Net Cash From Continuing Financing Activities	-3.32	-246	19	9.48	-0.49	-250	4.10	2.45	-165	6.33	-12
Other Financing Activities, net	-3.32	-	-	-	-0.49	-	-	-	-1.05	-	-

This table presents Halozyme Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Total Assets	2,063	1,733	1,842	1,104	580	566	440	520	262	182
Total Current Assets	1,085	746	739	926	555	543	428	510	257	172
Cash & Equivalents	116	118	234	119	148	120	58	169	67	43
Short-Term Investments	480	218	129	622	220	301	297	300	138	65
Accounts Receivable	308	234	231	91	98	59	30	22	16	32
Inventories, net	142	128	100	54	61	29	23	5.15	15	9.49
Prepaid Expenses	39	49	45	40	28	33	21	14	21	22
Plant, Property, & Equipment, net	0.00	0.00	0.00	0.00	0.00	11	7.47	3.52	4.26	3.94
Total Noncurrent Assets	978	987	1,102	178	25	12	4.93	6.05	0.72	6.07
Goodwill	417	417	409	0.00	-	-	-	-	-	-
Intangible Assets	402	473	547	0.00	-	-	-	-	-	-
Noncurrent Deferred & Refundable Income Taxes	3.86	4.39	44	155	0.00	-	-	-	-	-
Other Noncurrent Operating Assets	156	93	102	22	25	11	4.43	5.55	0.22	5.57
Total Liabilities & Shareholders' Equity	2,063	1,733	1,842	1,104	580	566	440	520	262	182
Total Liabilities	1,700	1,649	1,672	907	429	474	191	312	294	139
Total Current Liabilities	139	112	131	117	421	86	149	131	55	62
Accounts Payable	10	12	18	1.54	1.93	6.43	4.08	7.95	3.58	4.50
Accrued Expenses	129	101	100	24	20	56	50	40	29	27
Total Noncurrent Liabilities	1,561	1,537	1,541	790	7.49	388	42	180	239	76
Long-Term Debt	1,506	1,499	1,493	787	0.00	383	35	125	199	28
Other Noncurrent Operating Liabilities	55	38	48	0.54	3.47	4.18	2.12	0.81	0.36	4.44
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	364	84	170	197	151	92	249	208	-32	43
Total Preferred & Common Equity	364	84	170	197	151	92	249	208	-32	43
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	364	84	170	197	151	92	249	208	-32	43
Common Stock	0.12	2.54	28	256	626	695	781	731	553	526
Retained Earnings	360	91	143	-59	-475	-604	-531	-522	-585	-483
Accumulated Other Comprehensive Income / (Loss)	3.83	-9.28	-0.92	-0.62	0.02	0.24	-0.28	-0.45	-0.01	-0.10

This table presents Halozyme Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	3/31/2025	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	2,197	2,118	1,969	1,842	1,893	1,810	1,699	1,865
Total Current Assets	1,262	1,127	988	874	879	766	615	653
Cash & Equivalents	176	154	188	165	274	221	96	147
Short-Term Investments	572	512	341	299	209	127	179	118
Accounts Receivable	305	286	215	196	217	246	195	233
Inventories, net	165	131	159	169	129	132	108	103
Prepaid Expenses	45	44	85	46	49	39	37	51
Plant, Property, & Equipment, net	73	0.00	0.00	78	0.00	0.00	0.00	0.00
Total Noncurrent Assets	862	991	982	890	1,014	1,045	1,084	1,211
Goodwill	417	417	417	417	417	417	416	199
Intangible Assets	384	420	437	455	491	511	529	949
Noncurrent Deferred & Refundable Income Taxes	5.19	0.00	0.00	0.62	13	24	36	0.00
Other Noncurrent Operating Assets	56	155	127	17	93	93	103	62
Total Liabilities & Shareholders' Equity	2,197	2,118	1,969	1,842	1,893	1,810	1,699	1,865
Total Liabilities	1,714	1,665	1,680	1,664	1,643	1,659	1,634	1,768
Total Current Liabilities	150	109	133	132	115	116	92	109
Accounts Payable	20	12	15	13	19	10	8.70	18
Accrued Expenses	130	96	118	118	95	105	80	74
Total Noncurrent Liabilities	1,564	1,557	1,547	1,532	1,528	1,543	1,542	1,658
Long-Term Debt	1,507	1,504	1,503	1,501	1,498	1,496	1,494	1,491
Other Noncurrent Operating Liabilities	56	40	31	31	28	45	45	135
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	482	453	289	178	249	151	66	97
Total Preferred & Common Equity	482	453	289	178	249	151	66	97
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	482	453	289	178	249	151	66	97
Common Stock	7.72	62	31	12	26	12	0.13	13
Retained Earnings	478	398	261	167	222	140	66	86
Accumulated Other Comprehensive Income / (Loss)	-3.41	-6.94	-2.07	-1.49	1.23	-1.62	0.02	-1.84

This table displays calculated financial ratios and metrics derived from Halozyme Therapeutics' official financial filings.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	22.44%	25.62%	48.91%	65.67%	36.53%	29.06%	-52.04%	115.84%	8.61%	79.28%
EBITDA Growth	48.49%	34.41%	14.43%	70.24%	397.02%	7.17%	-169.84%	237.57%	-162.94%	58.28%
EBIT Growth	62.54%	31.77%	-3.04%	85.06%	346.90%	1.83%	-173.87%	202.09%	-202.94%	57.12%
NOPAT Growth	61.08%	25.62%	-51.41%	210.45%	404.29%	2.48%	-158.62%	242.14%	-203.11%	56.45%
Net Income Growth	57.71%	39.31%	-49.81%	211.97%	278.69%	10.07%	-227.57%	161.12%	-219.64%	52.86%
EPS Growth	63.33%	45.83%	-47.45%	201.10%	282.00%	10.71%	-224.44%	155.56%	-224.00%	55.36%
Operating Cash Flow Growth	23.29%	61.83%	-19.81%	439.98%	164.92%	-72.57%	-136.93%	366.07%	-35.87%	21.96%
Free Cash Flow Firm Growth	22.06%	144.35%	-359.01%	699.77%	136.96%	21.99%	-206.08%	327.63%	-9.96%	-16.13%
Invested Capital Growth	2.12%	-4.99%	295.12%	84.80%	147.64%	258.63%	134.31%	-176.45%	-33.32%	64.36%
Revenue Q/Q Growth	7.17%	6.22%	13.69%	-4.25%	34.09%	-3.24%	-45.99%	90.67%	-8.27%	19.30%
EBITDA Q/Q Growth	13.21%	10.56%	8.30%	-7.65%	196.37%	-114.45%	-195.44%	282.08%	-28.79%	26.26%
EBIT Q/Q Growth	15.31%	9.61%	7.40%	-7.18%	268.07%	-116.91%	-197.54%	227.38%	-51.48%	26.49%
NOPAT Q/Q Growth	12.73%	9.86%	-3.99%	-1.77%	317.93%	-89.81%	-181.68%	275.21%	-50.82%	25.34%
Net Income Q/Q Growth	13.15%	10.90%	-4.29%	-1.56%	499.73%	-80.74%	-275.86%	171.32%	-44.45%	22.93%
EPS Q/Q Growth	13.95%	12.30%	-2.70%	-2.14%	468.75%	-78.57%	-409.09%	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	18.89%	5.40%	-0.03%	11.80%	351.03%	-76.73%	-153.06%	483.41%	-1.14%	-62.47%
Free Cash Flow Firm Q/Q Growth	13.83%	5.68%	0.65%	13.50%	191.52%	-34.15%	-127,533.84%	496.01%	11.66%	-70.05%
Invested Capital Q/Q Growth	-1.32%	-1.30%	-1.71%	-2.57%	23.62%	2.67%	-5.12%	-54.51%	0.03%	62.45%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	84.30%	76.80%	78.90%	81.64%	83.79%	76.76%	93.33%	90.16%	77.36%	78.35%
EBITDA Margin	64.31%	53.03%	49.56%	64.49%	62.76%	-28.85%	-40.11%	27.55%	-43.22%	-17.85%
Operating Margin	54.32%	40.71%	40.53%	62.24%	53.91%	-34.50%	-45.65%	25.58%	-56.72%	-20.33%
EBIT Margin	56.65%	42.68%	40.69%	62.49%	55.94%	-30.93%	-40.66%	26.40%	-55.82%	-20.01%
Profit (Net Income) Margin	43.74%	33.96%	30.62%	90.84%	48.24%	-36.86%	-52.90%	19.89%	-70.23%	-23.86%
Tax Burden Percent	79.71%	80.84%	81.20%	162.04%	99.83%	99.98%	100.67%	102.21%	101.14%	100.00%
Interest Burden Percent	96.85%	98.43%	92.68%	89.72%	86.39%	119.18%	129.22%	73.70%	124.40%	119.24%
Effective Tax Rate	20.29%	19.16%	18.80%	-62.04%	0.17%	0.00%	0.00%	-2.21%	0.00%	0.00%
Return on Invested Capital (ROIC)	34.88%	21.32%	26.42%	174.65%	114.14%	-101.96%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	35.31%	22.08%	24.05%	120.53%	-198.82%	-81.86%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	163.54%	200.75%	83.81%	56.79%	-7.81%	59.55%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	198.42%	222.07%	110.23%	231.44%	106.33%	-42.41%	-35.14%	71.60%	-1,958.98%	-76.42%
Cash Return on Invested Capital (CROIC)	32.78%	26.44%	-92.80%	115.10%	29.20%	-214.75%	-631.24%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	30.30%	19.80%	18.23%	32.89%	26.13%	-12.05%	-12.86%	21.39%	-36.94%	-15.54%
Return on Assets (ROA)	23.39%	15.75%	13.72%	47.82%	22.53%	-14.36%	-16.73%	16.12%	-46.48%	-18.54%
Return on Common Equity (ROCE)	198.42%	222.07%	110.23%	231.44%	106.33%	-42.41%	-35.14%	71.60%	-1,958.98%	-76.42%
Return on Equity Simple (ROE_SIMPLE)	122.06%	336.00%	119.04%	204.47%	85.46%	-78.72%	-32.28%	30.22%	317.18%	-74.96%
Net Operating Profit after Tax (NOPAT)	440	273	217	447	144	-47	-49	83	-58	-19
NOPAT Margin	43.29%	32.91%	32.91%	100.85%	53.82%	-24.15%	-31.96%	26.15%	-39.71%	-14.23%
Net Nonoperating Expense Percent (NNEP)	-0.44%	-0.75%	2.37%	54.13%	312.95%	-20.11%	-12.82%	-15.47%	-187.09%	-17.92%
Return On Investment Capital (ROIC_SIMPLE)	23.51%	17.24%	12.96%	-	-	-	-	-	-	-
Cost of Revenue to Revenue	15.70%	23.20%	21.10%	18.36%	16.21%	23.24%	6.67%	9.84%	22.64%	21.65%
SG&A Expenses to Revenue	15.20%	17.99%	21.74%	11.35%	17.09%	39.42%	40.04%	17.00%	31.26%	29.64%
R&D to Revenue	7.79%	9.21%	10.09%	8.05%	12.79%	71.84%	98.94%	47.58%	102.83%	69.03%
Operating Expenses to Revenue	29.98%	36.09%	38.37%	19.40%	29.89%	111.26%	138.98%	64.58%	134.09%	98.67%
Earnings before Interest and Taxes (EBIT)	575	354	269	277	150	-61	-62	84	-82	-27
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	653	440	327	286	168	-57	-61	87	-63	-24
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	16.72	58.26	45.31	28.74	38.22	28.31	8.50	13.84	0.00	51.59
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	28.74	38.22	28.31	8.50	13.84	0.00	51.59
Price to Revenue (P/Rev)	5.99	5.89	11.66	12.77	21.58	13.26	13.93	9.11	8.72	16.43
Price to Earnings (P/E)	13.70	17.34	38.06	14.06	44.73	0.00	0.00	45.80	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	7.30%	5.77%	2.63%	7.11%	2.24%	0.00%	0.00%	2.18%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	5.49	4.85	6.73	17.45	32.28	35.53	93.21	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	6.89	7.29	13.39	13.08	21.69	13.16	12.42	8.27	8.80	15.99
Enterprise Value to EBITDA (EV/EBITDA)	10.71	13.75	27.01	20.28	34.55	0.00	0.00	30.01	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	12.16	17.08	32.90	20.93	38.77	0.00	0.00	31.31	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	15.91	22.15	40.68	12.97	40.29	0.00	0.00	31.61	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	14.60	15.56	36.80	19.36	104.64	0.00	0.00	19.52	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	16.93	17.86	0.00	19.67	157.51	0.00	0.00	21.73	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	4.14	17.89	8.87	4.45	2.63	4.39	0.51	0.97	-6.67	1.16
Long-Term Debt to Equity	4.14	17.89	8.79	4.00	0.00	4.17	0.14	0.60	-6.13	0.65
Financial Leverage	4.63	9.09	3.48	0.47	0.04	-0.73	-1.08	-1.46	-4.55	-1.72
Leverage Ratio	8.48	14.10	8.03	4.84	4.72	2.95	2.10	4.44	42.15	4.12
Compound Leverage Factor	8.22	13.87	7.44	4.34	4.08	3.52	2.71	3.27	52.43	4.92
Debt to Total Capital	80.54%	94.71%	89.87%	81.66%	72.45%	81.44%	33.68%	49.27%	117.64%	53.68%
Short-Term Debt to Total Capital	0.00%	0.00%	0.80%	8.33%	72.45%	3.95%	24.38%	18.80%	9.45%	23.55%
Long-Term Debt to Total Capital	80.54%	94.71%	89.07%	73.33%	0.00%	77.48%	9.29%	30.47%	108.19%	30.13%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	19.46%	5.29%	10.13%	18.34%	27.55%	18.56%	66.32%	50.73%	-17.64%	46.32%
Debt to EBITDA	2.31	3.41	4.60	3.07	2.37	-7.12	-2.07	2.32	-3.42	-2.07
Net Debt to EBITDA	1.39	2.65	3.49	0.47	0.17	0.33	3.75	-3.06	-0.18	2.43
Long-Term Debt to EBITDA	2.31	3.41	4.56	2.75	0.00	-6.77	-0.57	1.43	-3.14	-1.16
Debt to NOPAT	3.43	5.49	6.93	1.96	2.76	-8.51	-2.60	2.44	-3.72	-2.59
Net Debt to NOPAT	2.07	4.26	5.26	0.30	0.20	0.39	4.70	-3.22	-0.20	3.04
Long-Term Debt to NOPAT	3.43	5.49	6.87	1.76	0.00	-8.09	-0.72	1.51	-3.42	-1.46
Altman Z-Score	4.35	3.44	4.11	5.78	8.52	2.76	5.58	6.16	-0.07	6.85
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	7.80	6.64	5.65	7.91	1.32	6.35	2.86	3.89	4.70	2.75
Quick Ratio	6.50	5.07	4.54	7.10	1.11	5.61	2.57	3.74	4.04	2.25
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	413	338	-763	295	37	-100	-128	120	-53	-48
Operating Cash Flow to CapEx	4,478.91%	2,540.68%	0.00%	20,551.82%	3,883.33%	-2,114.43%	-1,061.55%	8,710.40%	-1,606.09%	-1,571.31%
Free Cash Flow to Firm to Interest Expense	22.83	18.04	-38.82	10.34	1.81	-8.57	-7.08	5.48	-2.65	-9.25
Operating Cash Flow to Interest Expense	26.47	20.71	12.21	10.51	2.72	-7.35	-2.74	6.10	-2.52	-7.13
Operating Cash Flow Less CapEx to Interest Expense	25.88	19.90	13.29	10.46	2.65	-7.69	-3.00	6.03	-2.68	-7.58
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.53	0.46	0.45	0.53	0.47	0.39	0.32	0.81	0.66	0.78
Accounts Receivable Turnover	3.74	3.56	4.10	4.70	3.41	4.38	5.83	16.75	6.10	6.50
Inventory Turnover	1.18	1.69	1.81	1.42	0.96	1.75	0.73	3.15	2.75	3.68
Fixed Asset Turnover	0.00	0.00	0.00	0.00	0.00	21.40	27.65	81.35	35.75	39.18
Accounts Payable Turnover	14.45	13.04	14.49	46.94	10.37	8.66	1.69	5.41	8.22	7.80
Days Sales Outstanding (DSO)	97.54	102.40	89.04	77.69	107.19	83.29	62.66	21.80	59.83	56.16
Days Inventory Outstanding (DIO)	308.48	216.05	201.79	257.02	379.19	208.30	500.02	115.81	132.52	99.19
Days Payable Outstanding (DPO)	25.26	28.00	25.20	7.78	35.19	42.12	216.55	67.52	44.39	46.82
Cash Conversion Cycle (CCC)	380.76	290.45	265.63	326.93	451.19	249.46	346.13	70.09	147.96	108.53
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	1,274	1,247	1,313	332	180	73	20	-59	-21	-16
Invested Capital Turnover	0.81	0.65	0.80	1.73	2.12	4.22	-7.84	-7.88	-7.86	-4.43
Increase / (Decrease) in Invested Capital	26	-66	980	152	107	52	79	-38	-5.33	29
Enterprise Value (EV)	6,992	6,046	8,837	5,797	5,803	2,579	1,887	2,617	1,291	2,160
Market Capitalization	6,083	4,882	7,694	5,661	5,774	2,598	2,115	2,884	1,279	2,218
Book Value per Share	$2.86	$0.63	$1.26	$1.40	$1.12	$0.63	$1.72	$1.46	($0.25)	$0.34
Tangible Book Value per Share	($3.57)	($6.10)	($5.81)	$1.40	$1.12	$0.63	$1.72	$1.46	($0.25)	$0.34
Total Capital	1,870	1,583	1,676	1,074	548	494	375	411	184	93
Total Debt	1,506	1,499	1,506	877	397	403	126	202	217	50
Total Long-Term Debt	1,506	1,499	1,493	787	0.00	383	35	125	199	28
Net Debt	910	1,163	1,143	136	29	-19	-228	-267	12	-59
Capital Expenditures (CapEx)	11	15	-21	1.46	1.43	4.04	4.66	1.54	3.14	2.36
Debt-free, Cash-free Net Working Capital (DFCFNWC)	350	298	259	158	163	56	15	-13	14	23
Debt-free Net Working Capital (DFNWC)	946	634	622	899	531	477	370	456	219	131
Net Working Capital (NWC)	946	634	608	809	133	458	278	379	202	109
Net Nonoperating Expense (NNE)	-4.51	-8.69	15	44	15	25	32	20	45	13
Net Nonoperating Obligations (NNO)	910	1,163	1,143	135	29	-19	-229	-267	11	-59
Total Depreciation and Amortization (D&A)	78	86	59	8.90	18	4.08	0.84	3.62	18	2.92
Debt-free, Cash-free Net Working Capital to Revenue	34.49%	35.93%	39.20%	35.56%	60.76%	28.61%	10.19%	-4.09%	9.79%	16.91%
Debt-free Net Working Capital to Revenue	93.20%	76.45%	94.16%	202.69%	198.29%	243.55%	243.64%	144.10%	149.53%	97.13%
Net Working Capital to Revenue	93.20%	76.45%	92.14%	182.52%	49.84%	233.58%	183.38%	119.72%	137.67%	80.94%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$3.50	$2.13	$1.48	$2.86	$0.95	$0.00	($0.56)	$0.46	($0.81)	($0.25)
Adjusted Weighted Average Basic Shares Outstanding	126.83M	131.93M	136.84M	140.65M	136.21M	144.33M	143.60M	136.42M	129.76M	129.06M
Adjusted Diluted Earnings per Share	$3.43	$2.10	$1.44	$2.74	$0.91	($0.50)	($0.56)	$0.45	($0.81)	($0.25)
Adjusted Weighted Average Diluted Shares Outstanding	129.42M	134.20M	140.61M	146.80M	141.46M	144.33M	143.60M	139.07M	129.76M	129.06M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	($0.50)	$0.00	$0.00	($0.81)	($0.25)
Adjusted Weighted Average Basic & Diluted Shares Outstanding	123.15M	126.82M	135.37M	137.70M	135.28M	144.33M	145.03M	143.08M	127.96M	126.70M
Normalized Net Operating Profit after Tax (NOPAT)	440	273	217	193	144	-47	-49	57	-58	-19
Normalized NOPAT Margin	43.29%	32.91%	32.91%	43.57%	53.82%	-24.15%	-31.96%	17.91%	-39.71%	-14.23%
Pre Tax Income Margin	54.87%	42.01%	37.71%	56.06%	48.32%	-36.86%	-52.54%	19.46%	-69.44%	-23.86%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	31.79	18.86	13.66	9.72	7.35	-5.21	-3.42	3.80	-4.10	-5.20
NOPAT to Interest Expense	24.29	14.55	11.05	15.69	7.07	-4.07	-2.69	3.77	-2.92	-3.69
EBIT Less CapEx to Interest Expense	31.20	18.05	14.74	9.67	7.28	-5.56	-3.68	3.73	-4.26	-5.65
NOPAT Less CapEx to Interest Expense	23.70	13.73	12.13	15.64	7.00	-4.42	-2.95	3.70	-3.07	-4.15
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	56.29%	142.89%	98.95%	86.93%	116.29%	-276.85%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Halozyme Therapeutics' official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	35.22%	29.55%	34.28%	4.67%	20.81%	26.75%	3.38%	45.07%	38.25%	77.93%	80.42%
EBITDA Growth	40.54%	60.26%	62.05%	19.15%	53.80%	49.75%	-0.65%	152.32%	-0.38%	42.27%	50.02%
EBIT Growth	47.56%	71.77%	82.31%	25.21%	77.06%	41.18%	10.88%	194.88%	-25.45%	32.53%	10.64%
NOPAT Growth	52.04%	58.23%	90.71%	22.49%	87.33%	40.40%	1.93%	194.41%	-33.25%	-11.82%	-68.47%
Net Income Growth	53.72%	60.46%	67.42%	24.74%	93.92%	47.98%	32.78%	229.53%	-34.09%	-13.58%	-71.54%
EPS Growth	55.00%	65.63%	72.13%	28.57%	106.90%	56.10%	38.64%	250.00%	-32.56%	-8.89%	-70.27%
Operating Cash Flow Growth	19.16%	74.36%	-12.87%	-16.53%	48.83%	24.14%	90.15%	66.17%	81.94%	-0.08%	-42.80%
Free Cash Flow Firm Growth	-38.31%	-28.10%	-24.14%	20.80%	116.29%	116.40%	115.45%	110.00%	-685.46%	-1,000.44%	-3,745.63%
Invested Capital Growth	2.19%	2.12%	2.14%	-2.76%	-5.36%	-4.99%	-5.38%	-2.31%	265.57%	295.12%	291.65%
Revenue Q/Q Growth	-11.12%	2.73%	25.39%	18.11%	-14.85%	6.48%	-2.26%	36.32%	-10.66%	-13.15%	37.15%
EBITDA Q/Q Growth	-16.62%	7.35%	33.49%	17.63%	-4.92%	8.54%	-1.85%	51.84%	-7.43%	-27.99%	149.30%
EBIT Q/Q Growth	-18.82%	7.71%	38.77%	21.62%	-5.51%	14.32%	-4.70%	71.98%	-24.65%	-10.21%	153.46%
NOPAT Q/Q Growth	-13.87%	-0.34%	45.83%	21.47%	-10.36%	20.11%	-6.34%	85.78%	-32.82%	-12.80%	170.53%
Net Income Q/Q Growth	-13.81%	0.00%	46.94%	21.38%	-10.03%	4.34%	9.48%	88.70%	-31.35%	-6.38%	171.70%
EPS Q/Q Growth	-12.26%	0.95%	45.83%	20.00%	-6.25%	4.92%	8.93%	93.10%	-29.27%	-6.82%	175.00%
Operating Cash Flow Q/Q Growth	-13.59%	54.68%	106.79%	-56.89%	26.45%	-22.70%	98.10%	-23.14%	5.47%	18.41%	73.11%
Free Cash Flow Firm Q/Q Growth	-17.32%	0.07%	-15.80%	-11.44%	-3.65%	5.58%	34.10%	111.94%	3.00%	0.55%	13.17%
Invested Capital Q/Q Growth	-2.49%	-1.32%	2.19%	3.92%	-2.55%	-1.30%	-2.71%	1.14%	-2.17%	-1.71%	0.44%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	81.73%	85.89%	82.96%	82.88%	85.54%	77.27%	74.62%	77.35%	78.31%	76.79%	77.36%
EBITDA Margin	63.78%	67.99%	65.07%	61.12%	61.37%	54.96%	53.92%	53.69%	48.20%	46.52%	56.11%
Operating Margin	53.44%	58.89%	56.26%	50.67%	48.78%	43.92%	40.86%	42.73%	33.18%	41.05%	39.86%
EBIT Margin	56.01%	61.33%	58.49%	52.85%	51.33%	46.25%	43.08%	44.18%	35.02%	41.52%	40.16%
Profit (Net Income) Margin	44.59%	45.98%	47.23%	40.30%	39.22%	37.12%	37.88%	33.82%	24.43%	31.79%	29.49%
Tax Burden Percent	82.11%	76.88%	82.96%	79.19%	80.00%	84.40%	80.42%	80.25%	75.84%	81.51%	83.62%
Interest Burden Percent	96.95%	97.52%	97.33%	96.30%	95.52%	95.09%	109.34%	95.40%	92.00%	93.94%	87.82%
Effective Tax Rate	17.89%	23.12%	17.04%	20.81%	20.00%	15.60%	19.58%	19.75%	24.16%	18.49%	16.38%
Return on Invested Capital (ROIC)	38.73%	36.48%	34.62%	27.36%	26.95%	24.02%	19.74%	20.19%	21.70%	26.86%	23.09%
ROIC Less NNEP Spread (ROIC-NNEP)	38.94%	36.68%	34.80%	27.40%	26.98%	24.03%	20.71%	20.09%	21.51%	26.38%	21.85%
Return on Net Nonoperating Assets (RNNOA)	106.00%	169.85%	91.83%	131.96%	249.78%	218.49%	134.75%	98.79%	86.38%	91.95%	74.89%
Return on Equity (ROE)	144.72%	206.32%	126.46%	159.32%	276.73%	242.50%	154.49%	118.98%	108.07%	118.80%	97.98%
Cash Return on Invested Capital (CROIC)	36.86%	32.78%	28.42%	28.21%	30.19%	26.44%	24.65%	21.11%	-90.02%	-92.80%	-91.65%
Operating Return on Assets (OROA)	30.08%	32.80%	27.63%	24.42%	25.02%	21.46%	17.90%	19.03%	17.25%	18.61%	15.29%
Return on Assets (ROA)	23.95%	24.59%	22.31%	18.62%	19.12%	17.22%	15.74%	14.57%	12.04%	14.25%	11.23%
Return on Common Equity (ROCE)	144.72%	206.32%	126.46%	159.32%	276.73%	242.50%	154.49%	118.98%	108.07%	118.80%	97.98%
Return on Equity Simple (ROE_SIMPLE)	100.64%	0.00%	86.69%	116.54%	179.30%	0.00%	101.90%	154.74%	275.83%	0.00%	217.75%
Net Operating Profit after Tax (NOPAT)	116	135	135	93	76	85	71	76	41	61	70
NOPAT Margin	43.88%	45.28%	46.67%	40.13%	39.02%	37.07%	32.86%	34.29%	25.16%	33.46%	33.33%
Net Nonoperating Expense Percent (NNEP)	-0.21%	-0.20%	-0.17%	-0.04%	-0.03%	-0.01%	-0.96%	0.10%	0.18%	0.47%	1.24%
Return On Investment Capital (ROIC_SIMPLE)	5.84%	7.22%	-	-	-	5.39%	-	-	-	3.62%	-
Cost of Revenue to Revenue	18.27%	14.11%	17.04%	17.12%	14.46%	22.73%	25.38%	22.65%	21.69%	23.21%	22.64%
SG&A Expenses to Revenue	15.99%	14.18%	14.22%	15.44%	17.94%	16.35%	16.33%	17.62%	23.04%	20.80%	16.49%
R&D to Revenue	5.59%	6.86%	6.36%	9.09%	9.76%	9.27%	8.02%	8.92%	11.09%	12.43%	7.99%
Operating Expenses to Revenue	28.29%	27.00%	26.70%	32.21%	36.76%	33.34%	33.76%	34.61%	45.13%	35.74%	37.50%
Earnings before Interest and Taxes (EBIT)	148	183	170	122	101	106	93	98	57	75	84
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	169	203	189	141	120	126	116	119	78	84	117
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	16.29	16.72	16.02	23.03	30.22	58.26	20.22	31.45	78.51	45.31	56.17
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	7.25	5.99	7.65	7.63	6.23	5.89	6.45	6.14	7.33	11.66	9.38
Price to Earnings (P/E)	16.19	13.70	18.48	19.76	16.86	17.34	19.85	20.32	28.46	38.06	25.79
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	6.18%	7.30%	5.41%	5.06%	5.93%	5.77%	5.04%	4.92%	3.51%	2.63%	3.88%
Enterprise Value to Invested Capital (EV/IC)	6.94	5.49	6.27	6.05	5.28	4.85	4.79	4.54	4.97	6.73	5.01
Enterprise Value to Revenue (EV/Rev)	7.95	6.89	8.54	8.75	7.43	7.29	7.75	7.62	9.06	13.39	11.52
Enterprise Value to EBITDA (EV/EBITDA)	12.28	10.71	14.02	15.14	13.31	13.75	15.22	14.80	19.54	27.01	22.14
Enterprise Value to EBIT (EV/EBIT)	13.83	12.16	16.21	18.09	16.12	17.08	18.75	18.80	25.64	32.90	26.74
Enterprise Value to NOPAT (EV/NOPAT)	17.98	15.91	20.74	23.47	20.79	22.15	24.37	23.90	32.46	40.68	29.55
Enterprise Value to Operating Cash Flow (EV/OCF)	17.10	14.60	20.07	18.19	14.87	15.56	16.42	19.28	22.87	36.80	27.84
Enterprise Value to Free Cash Flow (EV/FCFF)	19.03	16.93	22.29	21.14	16.99	17.86	18.90	21.25	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	3.13	4.14	3.32	5.19	8.44	17.89	6.01	9.91	22.69	8.87	15.51
Long-Term Debt to Equity	3.13	4.14	3.32	5.19	8.44	17.89	6.01	9.91	22.69	8.79	15.37
Financial Leverage	2.72	4.63	2.64	4.82	9.26	9.09	6.51	4.92	4.01	3.48	3.43
Leverage Ratio	6.12	8.48	5.71	8.58	14.53	14.10	10.85	8.09	8.78	8.03	8.05
Compound Leverage Factor	5.93	8.27	5.56	8.26	13.88	13.40	11.87	7.71	8.07	7.55	7.07
Debt to Total Capital	75.76%	80.54%	76.87%	83.85%	89.41%	94.71%	85.74%	90.83%	95.78%	89.87%	93.94%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.80%	0.83%
Long-Term Debt to Total Capital	75.76%	80.54%	76.87%	83.85%	89.41%	94.71%	85.74%	90.83%	95.78%	89.07%	93.11%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	24.24%	19.46%	23.13%	16.15%	10.59%	5.29%	14.27%	9.17%	4.22%	10.13%	6.06%
Debt to EBITDA	2.15	2.31	2.61	2.98	3.12	3.41	3.77	3.75	4.57	4.60	4.98
Net Debt to EBITDA	1.08	1.39	1.45	1.93	2.15	2.65	2.55	2.88	3.73	3.49	4.10
Long-Term Debt to EBITDA	2.15	2.31	2.61	2.98	3.12	3.41	3.77	3.75	4.57	4.56	4.94
Debt to NOPAT	3.14	3.43	3.86	4.62	4.87	5.49	6.03	6.06	7.59	6.93	6.65
Net Debt to NOPAT	1.58	2.07	2.15	2.99	3.36	4.26	4.08	4.65	6.19	5.26	5.48
Long-Term Debt to NOPAT	3.14	3.43	3.86	4.62	4.87	5.49	6.03	6.06	7.59	6.87	6.59
Altman Z-Score	4.38	3.73	4.16	3.73	3.20	2.97	3.06	2.86	2.85	3.76	2.72
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	8.39	7.80	10.36	7.41	6.64	6.64	7.63	6.58	6.69	5.65	5.97
Quick Ratio	7.00	6.50	8.75	5.58	5.01	5.07	6.08	5.11	5.12	4.54	4.56
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	90	108	108	129	145	151	143	107	-892	-920	-925
Operating Cash Flow to CapEx	16,233.79%	5,847.54%	7,605.54%	2,160.88%	3,650.97%	3,942.76%	4,497.66%	0.00%	764.38%	0.00%	6,908.23%
Free Cash Flow to Firm to Interest Expense	19.81	23.88	23.95	28.45	32.24	28.89	31.71	23.71	-196.36	-201.24	-90.43
Operating Cash Flow to Interest Expense	34.08	39.31	25.50	12.33	28.72	19.61	29.39	14.87	19.14	18.04	6.81
Operating Cash Flow Less CapEx to Interest Expense	33.87	38.64	25.17	11.76	27.93	19.11	28.74	15.23	16.64	19.71	6.71
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.54	0.53	0.47	0.46	0.49	0.46	0.42	0.43	0.49	0.45	0.38
Accounts Receivable Turnover	4.33	3.74	3.77	3.79	4.42	3.56	3.47	3.55	4.57	4.10	3.36
Inventory Turnover	1.08	1.18	1.30	1.20	1.34	1.69	1.57	1.52	2.04	1.81	1.49
Fixed Asset Turnover	14.37	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Payable Turnover	10.75	14.45	10.70	13.70	16.85	13.04	9.72	15.63	31.83	14.49	11.05
Days Sales Outstanding (DSO)	84.24	97.54	96.91	96.28	82.64	102.40	105.34	102.74	79.90	89.04	108.57
Days Inventory Outstanding (DIO)	339.00	308.48	280.04	304.12	271.57	216.05	232.60	240.32	178.74	201.79	244.71
Days Payable Outstanding (DPO)	33.96	25.26	34.12	26.64	21.66	28.00	37.55	23.35	11.47	25.20	33.02
Cash Conversion Cycle (CCC)	389.28	380.76	342.83	373.76	332.55	290.45	300.39	319.71	247.17	265.63	320.25
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	1,242	1,274	1,291	1,263	1,215	1,247	1,264	1,299	1,284	1,313	1,335
Invested Capital Turnover	0.88	0.81	0.74	0.68	0.69	0.65	0.60	0.59	0.86	0.80	0.69
Increase / (Decrease) in Invested Capital	27	26	27	-36	-69	-66	-72	-31	933	980	994
Enterprise Value (EV)	8,618	6,992	8,089	7,638	6,411	6,046	6,054	5,897	6,388	8,837	6,687
Market Capitalization	7,858	6,083	7,251	6,664	5,374	4,882	5,039	4,750	5,170	7,694	5,448
Book Value per Share	$3.92	$2.86	$3.57	$2.27	$1.40	$0.63	$1.89	$1.15	$0.49	$1.26	$0.70
Tangible Book Value per Share	($2.59)	($3.57)	($3.03)	($4.44)	($5.47)	($6.10)	($4.99)	($5.90)	($6.49)	($5.81)	($7.63)
Total Capital	1,990	1,870	1,957	1,792	1,679	1,583	1,747	1,647	1,560	1,676	1,601
Total Debt	1,507	1,506	1,504	1,503	1,501	1,499	1,498	1,496	1,494	1,506	1,504
Total Long-Term Debt	1,507	1,506	1,504	1,503	1,501	1,499	1,498	1,496	1,494	1,493	1,491
Net Debt	760	910	838	973	1,037	1,163	1,014	1,148	1,219	1,143	1,239
Capital Expenditures (CapEx)	0.95	3.05	1.52	2.58	3.55	2.60	2.94	-1.62	11	-7.64	1.01
Debt-free, Cash-free Net Working Capital (DFCFNWC)	364	350	352	325	278	298	281	301	247	259	292
Debt-free Net Working Capital (DFNWC)	1,112	946	1,018	854	742	634	764	649	523	622	557
Net Working Capital (NWC)	1,112	946	1,018	854	742	634	764	649	523	608	544
Net Nonoperating Expense (NNE)	-1.88	-2.09	-1.62	-0.40	-0.39	-0.12	-11	1.04	1.19	3.03	8.02
Net Nonoperating Obligations (NNO)	760	910	838	973	1,037	1,163	1,014	1,148	1,218	1,143	1,238
Total Depreciation and Amortization (D&A)	21	20	19	19	20	20	23	21	21	9.07	33
Debt-free, Cash-free Net Working Capital to Revenue	33.54%	34.49%	37.14%	37.26%	32.27%	35.93%	35.93%	38.92%	35.11%	39.20%	50.21%
Debt-free Net Working Capital to Revenue	102.52%	93.20%	107.47%	97.84%	85.97%	76.45%	97.84%	83.93%	74.20%	94.16%	95.95%
Net Working Capital to Revenue	102.52%	93.20%	107.47%	97.84%	85.97%	76.45%	97.84%	83.93%	74.20%	92.14%	93.66%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.96	$1.08	$1.08	$0.73	$0.61	$0.65	$0.62	$0.57	$0.29	$0.43	$0.45
Adjusted Weighted Average Basic Shares Outstanding	123.22M	126.83M	126.85M	127.12M	126.94M	131.93M	131.97M	131.73M	135.03M	136.84M	136.53M
Adjusted Diluted Earnings per Share	$0.93	$1.06	$1.05	$0.72	$0.60	$0.64	$0.61	$0.56	$0.29	$0.41	$0.44
Adjusted Weighted Average Diluted Shares Outstanding	126.64M	129.42M	130.13M	129.22M	128.89M	134.20M	134.08M	133.54M	137.90M	140.61M	139.39M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	123.22M	123.15M	127.23M	126.68M	127.27M	126.82M	132.10M	131.92M	131.68M	135.37M	135.21M
Normalized Net Operating Profit after Tax (NOPAT)	116	135	135	93	76	85	71	76	41	61	70
Normalized NOPAT Margin	43.88%	45.28%	46.67%	40.13%	39.02%	37.07%	32.86%	34.29%	25.16%	33.46%	33.33%
Pre Tax Income Margin	54.30%	59.80%	56.93%	50.89%	49.02%	43.98%	47.10%	42.14%	32.22%	39.00%	35.27%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	32.79	40.25	37.50	27.03	22.31	20.38	20.66	21.73	12.50	16.49	8.21
NOPAT to Interest Expense	25.68	29.72	29.93	20.52	16.96	16.34	15.76	16.87	8.98	13.29	6.81
EBIT Less CapEx to Interest Expense	32.58	39.58	37.17	26.46	21.52	19.88	20.00	22.09	9.99	18.16	8.11
NOPAT Less CapEx to Interest Expense	25.47	29.05	29.59	19.95	16.17	15.84	15.11	17.23	6.48	14.96	6.71
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	56.29%	64.29%	74.80%	79.14%	142.89%	59.11%	149.80%	192.74%	98.95%	170.61%

Frequently Asked Questions About Halozyme Therapeutics' Financials

When does Halozyme Therapeutics's fiscal year end?

According to the most recent income statement we have on file, Halozyme Therapeutics' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Halozyme Therapeutics' net income changed over the last 9 years?

Halozyme Therapeutics' net income appears to be on an upward trend, with a most recent value of $444.09 million in 2024, falling from -$32.23 million in 2015. The previous period was $281.59 million in 2023. View Halozyme Therapeutics' forecast to see where analysts expect Halozyme Therapeutics to go next.

What is Halozyme Therapeutics's operating income?

Halozyme Therapeutics's total operating income in 2024 was $551.48 million, based on the following breakdown:

Total Gross Profit: $855.91 million
Total Operating Expenses: $304.43 million

How has Halozyme Therapeutics revenue changed over the last 9 years?

Over the last 9 years, Halozyme Therapeutics' total revenue changed from $135.06 million in 2015 to $1.02 billion in 2024, a change of 651.8%.

How much debt does Halozyme Therapeutics have?

Halozyme Therapeutics' total liabilities were at $1.70 billion at the end of 2024, a 3.0% increase from 2023, and a 1,124.6% increase since 2015.

How much cash does Halozyme Therapeutics have?

In the past 9 years, Halozyme Therapeutics' cash and equivalents has ranged from $43.29 million in 2015 to $234.20 million in 2022, and is currently $115.85 million as of their latest financial filing in 2024.

How has Halozyme Therapeutics' book value per share changed over the last 9 years?

Over the last 9 years, Halozyme Therapeutics' book value per share changed from 0.34 in 2015 to 2.86 in 2024, a change of 751.3%.

Related Companies

This page (NASDAQ:HALO) was last updated on 5/25/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Halozyme Therapeutics (HALO) Financials

Frequently Asked Questions About Halozyme Therapeutics' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Halozyme Therapeutics (HALO) Financials

Annual Income Statements for Halozyme Therapeutics

Quarterly Income Statements for Halozyme Therapeutics

Annual Cash Flow Statements for Halozyme Therapeutics

Quarterly Cash Flow Statements for Halozyme Therapeutics

Annual Balance Sheets for Halozyme Therapeutics

Quarterly Balance Sheets for Halozyme Therapeutics

Annual Metrics And Ratios for Halozyme Therapeutics

Quarterly Metrics And Ratios for Halozyme Therapeutics

Frequently Asked Questions About Halozyme Therapeutics' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools